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Abstract: BACKGROUND The clinical utility of procalcitonin in the diagnosis and management of pneu-
monia remains controversial. METHODS We assessed the clinical utility of procalcitonin in 2 prospective
studies: first, a multicenter diagnostic study in patients presenting to the emergency department with
acute dyspnea to directly compare the diagnostic accuracy of procalcitonin with that of interleukin 6
and C-reactive protein (CRP) in the diagnosis of pneumonia; second, a randomized management study
of procalcitonin guidance in patients with acute heart failure and suspected pneumonia. Diagnostic ac-
curacy for pneumonia as centrally adjudicated by 2 independent experts was quantified with the area
under the ROC curve (AUC). RESULTS Among 690 patients in the diagnostic study, 178 (25.8%) had an
adjudicated final diagnosis of pneumonia. Procalcitonin, interleukin 6, and CRP were significantly higher
in patients with pneumonia than in those without. When compared to procalcitonin (AUC = 0.75; 95%
CI, 0.71-0.78), interleukin 6 (AUC = 0.80; 95% CI, 0.77-0.83) and CRP (AUC = 0.82; 95% CI, 0.79-0.85)
had significantly higher diagnostic accuracy (P = 0.010 and P < 0.001, respectively). The management
study was stopped early owing to the unexpectedly low AUC of procalcitonin in the diagnostic study.
Among 45 randomized patients, the number of days on antibiotic therapy and the length of hospital stay
were similar (both P = 0.39) in patients randomized to the procalcitonin-guided group (n = 25) and
usual-care group (n = 20). CONCLUSIONS In patients presenting with dyspnea, diagnostic accuracy of
procalcitonin for pneumonia is only moderate and lower than that of interleukin 6 and CRP. The clinical
utility of procalcitonin was lower than expected. SUMMARY Pneumonia has diverse and often unspecific
symptoms. As the role of biomarkers in the diagnosis of pneumonia remains controversial, it is often
difficult to distinguish pneumonia from other illnesses causing shortness of breath. The current study
prospectively enrolled unselected patients presenting with acute dyspnea and directly compared the diag-
nostic accuracy of procalcitonin, interleukin 6, and CRP for the diagnosis of pneumonia. In this setting,
diagnostic accuracy of procalcitonin for pneumonia was lower as compared to interleukin 6 and CRP.
The clinical utility of procalcitonin was lower than expected. CLINICALTRIALSGOV IDENTIFIER:
NCT01831115.
DOI: https://doi.org/10.1373/clinchem.2019.306787
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BACKGROUND: The clinical utility of procalcitonin in
the diagnosis and management of pneumonia remains
controversial.
METHODS: We assessed the clinical utility of procalci-
tonin in 2 prospective studies: first, a multicenter diag-
nostic study in patients presenting to the emergency de-
partment with acute dyspnea to directly compare the
diagnostic accuracy of procalcitonin with that of inter-
leukin 6 and C-reactive protein (CRP) in the diagnosis of
pneumonia; second, a randomized management study of
procalcitonin guidance in patients with acute heart fail-
ure and suspected pneumonia. Diagnostic accuracy for
pneumonia as centrally adjudicated by 2 independent
experts was quantified with the area under the ROC
curve (AUC).
RESULTS: Among 690 patients in the diagnostic study,
178 (25.8%) had an adjudicated final diagnosis of pneu-
monia. Procalcitonin, interleukin 6, and CRP were
significantly higher in patients with pneumonia than in
those without. When compared to procalcitonin
(AUC  0.75; 95% CI, 0.71–0.78), interleukin 6
(AUC  0.80; 95% CI, 0.77–0.83) and CRP (AUC 
0.82; 95% CI, 0.79–0.85) had significantly higher diag-
nostic accuracy (P  0.010 and P  0.001, respectively).
The management study was stopped early owing to the
unexpectedly low AUC of procalcitonin in the diagnostic
study. Among 45 randomized patients, the number of
days on antibiotic therapy and the length of hospital stay
were similar (both P  0.39) in patients randomized to
the procalcitonin-guided group (n  25) and usual-care
group (n  20).
CONCLUSIONS: In patients presenting with dyspnea, diag-
nostic accuracy of procalcitonin for pneumonia is only
moderate and lower than that of interleukin 6 and CRP.
The clinical utility of procalcitonin was lower than
expected.
SUMMARY: Pneumonia has diverse and often unspecific
symptoms. As the role of biomarkers in the diagnosis of
pneumonia remains controversial, it is often difficult to
distinguish pneumonia from other illnesses causing
shortness of breath. The current study prospectively en-
rolled unselected patients presenting with acute dyspnea
and directly compared the diagnostic accuracy of procal-
citonin, interleukin 6, and CRP for the diagnosis of
pneumonia. In this setting, diagnostic accuracy of pro-
calcitonin for pneumonia was lower as compared to in-
terleukin 6 and CRP. The clinical utility of procalcitonin
was lower than expected.
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© 2019 American Association for Clinical Chemistry
Pneumonia has diverse and often unspecific symptoms
such as cough, fever, or dyspnea. In dyspneic patients,
acute heart failure (AHF)11 is another common underly-
ing disorder and frequently occurs in parallel (1, 2 ). Al-
though the clinical introduction of natriuretic peptides as
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biomarkers has substantially facilitated the early diagno-
sis of AHF and their use is consistently recommended in
both US and European clinical practice guidelines (3–5 ),
the role of biomarkers in the diagnosis of pneumonia is
more controversial. For these reasons, early diagnosis
and management of patients with pneumonia is often
challenging.
In the absence of a large pivotal diagnostic study
directly comparing the currently available inflammatory
biomarkers, clinical practice guidelines differ in their
recommendations. For instance, for the diagnosis of
community-acquired pneumonia (CAP), British practice
guidelines recommend C-reactive protein (CRP) (6 ),
whereas the American Infectious Diseases Society of
America/American Thoracic Society guidelines favor
procalcitonin (7 ). Similar uncertainties relate to the use
of procalcitonin in tailoring the duration of antibiotic
therapy (8–12).
To address these unmet needs, we aimed to perform
2 prospective studies to investigate the clinical utility of
procalcitonin: first, a multicenter diagnostic study per-
formed in patients presenting with acute dyspnea to en-
sure broad inclusion criteria enrolling as many pneumo-
nia patients as possible to directly compare the diagnostic
accuracy of procalcitonin with that of interleukin 6 and
CRP; second, a randomized management study of pro-
calcitonin guidance in patients with pneumonia and con-
comitant AHF (13 ).
Methods
DIAGNOSTIC STUDY
Study design and study population. Basics in Acute Short-
ness of Breath Evaluation (BASEL V; ClinicalTrials.gov
registry, number NCT01831115) was a prospective,
multicenter, diagnostic study enrolling adult patients
presenting with acute dyspnea to the emergency depart-
ment (ED) of 2 university hospitals (Basel and Zurich,
Switzerland). To enroll as many pneumonia patients as
possible, acute dyspnea was the only criterion to be met,
with no other additional symptom suggestive of pneu-
monia. Patients were included irrespective of renal func-
tion, except for patients with terminal kidney failure on
chronic hemodialysis who were excluded. For this analy-
sis, patients were not eligible if they had unavailable
measurements of one or more investigated inflammatory
biomarkers (procalcitonin, interleukin 6, CRP) at time of
presentation.
The study was carried out according to the princi-
ples of the Declaration of Helsinki and was approved by
the local ethics committees. Written informed consent
was obtained from all patients. The authors designed the
study, gathered and analyzed the data according to the
Standards for Reporting of Diagnostic Accuracy Group
guidelines for studies of diagnostic accuracy (see Table 1
in the online Data Supplement), vouched for the data
and analysis, wrote the paper, and decided to publish.
Adjudication of the final diagnosis. The final diagnosis of
the illness causing shortness of breath was adjudicated by
2 independent cardiologist–internists who had access to
all patients’ medical records such as clinical history, phys-
ical examination, available laboratory findings, 12-lead
electrocardiogram, chest x-ray, echocardiography, CT of
the chest, microbiological findings, the response to ther-
apy, and autopsy data for patients who died in hospital.
All laboratory findings obtained through the clini-
cian’s routine diagnostic workup were available for the
adjudicating physician. These findings were defined as
internal measurements including one of the natriuretic
peptides with class I recommendation [B-type natri-
uretic peptide (BNP) or N-terminal pro-B-type natri-
uretic peptide (NT-proBNP)] (4, 5 ), white blood cell
count, and CRP. Physicians also were able to order
procalcitonin at their discretion. Adjudicating physi-
cians were blinded to measurements from study blood
samples. These measurements were defined as external
results including all interleukin 6 measurements and
procalcitonin measurements in patients in whom the
treating physician had not ordered procalcitonin as
part of the clinical diagnostic workup. In situations of
disagreement about the final diagnosis, cases were re-
viewed and adjudicated in conjunction with a third
cardiologist–internist.
Adjudicated pneumonia as primary end point. In cases of
pneumonia, diagnosed according to criteria from Fine et
al. and Leroy et al. (14, 15 ), all cases of pneumonia were
required to have a new infiltrate on chest x-ray or CT of
the chest, in combination with microbiological proof of
infection, or more than one of the major criteria. In cases
of equivocal chest imaging (interstitial pattern, effu-
sions), at least 2 major criteria were considered as
necessary.
All patient records and discharge papers of patients
with an adjudicated final diagnosis of pneumonia were
reviewed to classify them into CAP, hospital-acquired pneu-
monia (HAP), or healthcare-associated pneumonia
(HCAP) according to current practice guidelines (16, 17).
Pneumonia with proven specific bacterial pathogen. In pa-
tients with an adjudicated final diagnosis of pneumonia,
all available microbiological specimens and tests re-
quested by the treating physician were centrally re-
viewed by an experienced internist. Results were inter-
preted in conjunction with consequential changes in
antimicrobial therapy and the patient’s clinical status.
Therefore, in accordance with previous studies (18 ),
bacterial pneumonia was considered to be absent if one
of the following conditions were met: an alternative
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cause for pulmonary infiltrate was identified, only un-
specific growth was found during microbiological test-
ing, or the patient rapidly recovered without antimi-
crobial therapy. A microorganism was defined as a
causative agent of pneumonia, if detected in blood,
sputum, or bronchoalveolar lavage fluid culture or
there was a positive urine diagnostic result for Strepto-
coccus pneumoniae and Legionella pneumophila antigen.
Only microorganisms cultured from representative
sputum specimens according to Murray’s criteria were
considered (19 ). Identical microorganisms found in
more than 1 microbiological specimen or test in the
same patients were considered only once.
Biomarker measurements. At each patient’s presentation
to the ED, blood samples were collected in tubes con-
taining potassium EDTA. Internal measurements (all
CRP, 2/3 of procalcitonin measurements) were re-
quested by the attending ED physician and external
ones (all interleukin 6, 1/3 of procalcitonin measure-
ments) were gained from study blood samples, which
were centrifuged and afterwards frozen at 80 °C un-
til assayed in a blinded fashion in a dedicated core
laboratory.
In the rare case of both measurements available for the
same patient, the internal procalcitonin result was taken for
analysis. Regardless of measurement type (internal or exter-
nal), procalcitonin plasma concentration was quantified
with the same automated sandwich immunoassay using a
time-resolved amplified cryptate emission technology assay
(PCT Kryptor®, B.R.A.H.M.S.) with a detection limit of
0.02 ng/mL and a functional assay sensitivity of 0.06
ng/mL, according to the manufacturer. The interassay
coefficient of variation for concentrations 0.3 ng/mL
was 6% (10 ). CRP was measured with C-Reactive Pro-
tein Gen.3 immunoturbidimetric assay (Tina-quant®,
Roche) on Roche/Hitachi cobas c systems. The assay’s
limit of detection was 0.3 mg/L with a functional assay
sensitivity of 0.6 mg/L (20 ).
Interleukin 6 was measured with the Erenna® immu-
noassay (Singulex) system, which used a microparticle im-
munoassay and single-molecule counting in a capillary flow
system. The assay’s limit of detection was 0.01 pg/mL, with
lower and upper limits of quantification at 0.08 pg/mL and
50 pg/mL, respectively. Intraindividual variability and in-
terindividual variation were 6% and 13%, respectively (21).
RANDOMIZED MANAGEMENT STUDY
In a single-center study performed at the Instituto do
Coração in Sao Paulo, Brazil, adult patients with AHF
diagnosed in the ED who also had suspected pneumonia
were randomized to procalcitonin guidance for deter-
mining the duration of antibiotic therapy or to the hos-
pital’s standard antibiotic treatment scheme (control).
All patients underwent procalcitonin testing and
physical examination on day 0 (randomization) and day
5 after inclusion. Initially, all study physicians were
blinded to procalcitonin measurements.
In the control group, duration of antibiotic therapy
was determined by the treating physician blinded to pro-
calcitonin plasma concentrations. For patients random-
ized to the intervention group, antibiotic therapy was
maintained or suspended on day 5 by a well-trained study
physician who was then unblinded to procalcitonin mea-
surements directly after the plasma concentration was
obtained from the inhouse Instituto do Coração Labora-
tory of Clinical Analyzes.
The decision whether to stop antibiotics was based
on predefined procalcitonin cutoffs (22, 23 ): antibiotic
therapy was stopped if procalcitonin concentration was
0.25 ng/mL or with a decrease of 80% vs the con-
centration at randomization. At a procalcitonin plasma
concentration of 0.25 ng/mL without substantial de-
crease, antibiotic therapy was continued in consultation
with the treating physician. Procalcitonin concentration
at admission had no effect on randomization or the de-
cision to start antibiotic treatment.
The primary end point was the number of days on
antibiotic therapy. Secondary end points included the
duration of hospitalization, inhospital mortality, and the
diagnostic accuracy of procalcitonin and CRP for pneu-
monia as adjudicated with CT of the chest. Further de-
tails regarding study population and statistical methods
are described in the Methods section in the online Data
Supplement.
Biomarker measurement. Laboratory parameters on hos-
pitalized study patients such as complete blood count,
urea, creatinine, CRP, and BNP were collected as part of
the routine diagnostic workup prescribed by the treating
physician. However, physicians were blinded to procal-
citonin measurements derived from study blood samples.
These were measured with a miniVIDAS® instrument
(MS-10158120241, BioMérieux Clinical Diagnostics)
with the VIDAS® B.R.A.H.M.S. PCT™ assay. The
miniVIDAS system used enzyme-linked fluorescent as-
say technology, which combined the ELISA method with
a final fluorescence reading. According to the manufac-
turer, 200 L of heparinized plasma was sufficient, with
a time to result of 20 min. The given measuring range was
0.05–200 ng/mL (24, 25 ). All measurements were pro-
cessed directly inhouse in the Instituto do Coração Lab-
oratory of Clinical Analyzes.
STATISTICAL ANALYSES IN THE DIAGNOSTIC STUDY
ROC curves were constructed to assess the diagnostic
accuracy of procalcitonin, interleukin 6, and CRP for
pneumonia. Comparison of the areas under the ROC
curve (AUCs) was performed as proposed by DeLong
1534 Clinical Chemistry 65:12 (2019)






(n = 178) P valueb
Demographics
Age, years 74.0 (62.0–82.0) 74.0 (62.0–82.0) 74.5 (61.0–81.0) 0.987
Female sex 310 (44.9%) 239 (46.7%) 71 (39.9%) 0.137
BMI,c kg/m2 25.7 (22.0–30.1) 25.8 (22.2–30.1) 24.9 (21.3–29.3) 0.183
Recent history
Cough 482 (71.8%) 329 (66.5%) 153 (86.9%) <0.001
Sputum production 346 (51.6%) 226 (45.7%) 120 (68.6%) <0.001
Weight gain 138 (21.6%) 108 (23.1%) 30 (17.5%) 0.158
Clinical parameters at ED
Systolic BP, mmHg 139.3 (±26.3) 141.6 (±26.9) 132.9 (±23.5) <0.001
Diastolic BP, mmHg 80.7 (±18.0) 82.9 (±17.9) 74.43 (±16.6) <0.001
Heart rate, bpm 94.0 (79.0–110.0) 92.0 (77.0–109.0) 97.0 (84.0–113.0) 0.011
Temperature, °C 37.4 (36.9–38.0) 37.3 (36.8–37.8) 37.9 (37.3–39.0) <0.001
Pulse oximetry, % 95.0 (92.0–98.0) 96.0 (93.0–98.0) 94.0 (90.0–96.0) <0.001
Respiratory rate, breaths/min 24.0 (18.0–28.0) 24.0 (18.0–28.0) 24.0 (18.0–32.0) 0.023
Rales 336 (50.1%) 220 (44.2%) 116 (67.1%) <0.001
Increased JVP 132 (20.7%) 111 (23.4%) 21 (12.7%) 0.004
Edema 271 (40.0%) 220 (43.7%) 51 (29.3%) 0.001
History variables
CRI 173 (25.1%) 128 (25.1%) 45 (25.3%) 1
CAD 225 (32.7%) 164 (32.1%) 61 (34.3%) 0.643
PAD 100 (14.9%) 74 (14.9%) 26 (15.1%) 1
COPD 299 (43.4%) 215 (42.1%) 84 (47.2%) 0.254
DM 163 (23.7%) 121 (23.7%) 42 (23.6%) 1
Dyslipidemia 268 (39.3%) 199 (39.3%) 69 (39.2%) 1
Hypertension 478 (69.6%) 359 (70.5%) 119 (66.9%) 0.394
MI 120 (17.5%) 88 (17.2%) 32 (18.2%) 0.818
Pneumonia 175 (25.7%) 109 (21.5%) 66 (37.5%) <0.001
Smoker (current or
ex-smoker)
484 (72.8%) 350 (71.3%) 134 (77.0%) 0.165
Immunsuppressiond 100 (14.5%) 72 (14.1%) 28 (15.7%) 0.621
Outpatient medication
Aspirin 241 (35.1%) 170 (33.4%) 71 (39.9%) 0.122
ACE inhibitors 220 (32.0%) 173 (34.0%) 47 (26.4%) 0.063
Aldosterone inhibitors 55 (8.0%) 45 (8.9%) 10 (5.6%) 0.201
ARB 114 (16.7%) 78 (15.4%) 36 (20.3%) 0.159
Beta blockers 270 (39.5%) 210 (41.5%) 60 (33.7%) 0.075
Calcium channel blockers 142 (20.7%) 96 (18.9%) 46 (25.8%) 0.054
Diuretics 349 (50.9%) 259 (51.1%) 90 (50.6%) 0.931
Antibiotics 71 (10.3%) 40 (7.9%) 31 (17.4%) 0.001
Laboratory parameters
Hemoglobin, g/L 135.0 (122.0–148.0) 136.0 (122.0–150.0) 131.0 (119.0–142.0) 0.001
WBC, ×103/μL 10.2 (7.6–13.6) 9.4 (7.2–12.2) 12.6 (8.7–16.8) <0.001
Continued on page 1536
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(26 ). The sensitivity and negative predictive value of cur-
rently recommended rule-out cutoffs for inflammatory
conditions were calculated (27, 28 ). The percentage of
patients eligible for rule out of pneumonia was used to
quantify effectiveness. The effectiveness does not deter-
mine how many patients are correctly ruled out, it only
shows the number of patients triaged toward rule out
(given that the plasma concentration of the investiga-
tional parameters was below the cutoff) when presenting
to the ED irrespective of whether they have the final
diagnosis of pneumonia or not.
For nonnormally distributed data, correlations were
assessed by Spearman’s rank (rs) correlation coeffi-
cient. In the diagnostic study, 6 subgroup analyses
were predefined: in patients with only internal (that is,
available for the adjudicating physician) measure-
ments (1 ) or only external (that is, unavailable for the
adjudicating physician) measurements (2 ) of procalci-
tonin to address the potential effect of inclusion bias; in
patients with pneumonia and proven specific bacterial
pathogen (3); and in patients with final diagnosis of pneu-
monia with (4) or without (5) concurrent AHF. Further-
more, a sensitivity analysis including patients with at least 1
additional symptom suggestive of pneumonia (temperature
38.0 °C, cough, sputum production, or lung infiltrate)
was performed (6).
The interaction P values between the biomarker’s
AUC in the overall cohort and the biomarker’s AUC in a
specific subgroup were calculated with a logistic regres-
sion model for the prediction of pneumonia.
Statistical analyses were performed with SPSS for
Windows 25.0 (SPSS Inc.), R statistical Software Ver-
sion 3.4.3 (MathSoft), and MedCalc Version 17.9.7
(MedCalc, Software). All hypothesis testing was
2-tailed, and P values of 0.05 were considered to
indicate statistical significance. Statistical analyses per-
formed in the randomized management study are de-




Patients: demographics and characteristics. Overall, 690
patients had the 3 inflammatory biomarkers measured
and hence were eligible for the diagnostic analysis (see
Fig. 1 in the online Data Supplement). These patients
more often had symptoms and signs of pneumonia as
compared to patients without these measurements (see Ta-
ble 2 in the online Data Supplement). Median age was 74
years and 44.9% were women. AHF was the adjudicated
final diagnosis in 311 patients (45.1%) and pneumonia in
178 patients (25.8%), with 58 patients (8.4%) adjudicated
to have both AHF and concurrent pneumonia. Of 178 pa-
tients with an adjudicated final diagnosis of pneumonia,
150 (84.3%), 26 (14.6%), and 2 (1.1%) presented with
CAP, HCAP, and HAP, respectively.
Inflammatory biomarkers. In our diagnostic study, CRP
measurements were available for the adjudicating physi-
cian in all patients (100%), procalcitonin measurements
in 453 patients (65.5%), and interleukin 6 measurements
in no patient (0%). Procalcitonin, interleukin 6, and
CRP were significantly higher in patients with pneumo-
nia than in those without (Table 1). CRP and interleukin
6 (rs  0.69; P  0.001) as well as CRP and procalci-
tonin (rs  0.61; P  0.001) plasma concentrations were
moderately correlated. Procalcitonin and interleukin 6
plasma concentrations also showed a moderate correla-
tion (rs  0.54; P  0.001). When compared to procal-
citonin (AUC  0.75; 95% CI, 0.71–0.78), interleukin
Table 1. Baseline characteristics in the diagnostic study according to the presence or absence of pneumonia.a






(n = 178) P valueb
Investigational parameters
CRP, mg/L 23.3 (5.9–69.2) 13.2 (4.2–46.2) 96.6 (40.5–189.4) <0.001
Interleukin 6, ng/L 15.5 (6.0–47.9) 10.6 (4.4–25.0) 54.7 (22.7–211.3) <0.001
Procalcitonin, ng/mL 0.09 (0.05–0.19) 0.07 (0.05–0.14) 0.19 (0.09–0.63) <0.001
a Continuous variables are presented as means with SD; for nonnormal distribution, as medians with interquartile ranges. For comparison, t test or Mann–Whitney U-test were used
as appropriate. Categorical variables are shown as numbers and percentages. For comparison, Fisher’s exact test was used.
b
P value for comparison between non-pneumonia and pneumonia patients.
c BMI, bodymass index; BP, bloodpressure; JVP, jugular venous pressure; CRI, chronic renal insufficiency; CAD, coronary artery disease; PAD, peripheral artery disease; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; MI, myocardial infarction; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; WBC, white blood cells
count.
d Immunsuppression was defined as history of active cancer and/or chronic medication with ≥5 mg of oral prednisone or a dose equivalent.
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6 (AUC  0.80; 95% CI, 0.77–0.83) and CRP (AUC 
0.82; 95% CI, 0.79–0.85) had significantly higher diag-
nostic accuracy (P  0.010 and P  0.001, respectively;
see Table 3 in the online Data Supplement, Fig. 1A).
Subgroup analyses. Our findings were consistent in all
predefined subgroups because there was no subgroup in
which procalcitonin seemed to provide higher diagnostic
accuracy (Fig. 2), including patients in whom procalci-
tonin measurements were available for the adjudicating
physician (n  452; see Table 4 in the online Data Sup-
plement, Fig. 3A), patients with only unavailable procal-
citonin measurements (n  238; see Table 5 in the online
Data Supplement, Fig. 3B), patients in whom microbi-
ology workup was able to establish a specific bacterial (or
fungal) pathogen (n  36; see Tables 6, 7, 8, and 9 in the
online Data Supplement, Fig. 1B), patients with a final
diagnosis of pneumonia and concurrent AHF (n  58;
see Table 10 and Fig. 2A in the online Data Supplement),
in patients with pneumonia only (n  120; see Table 11
and Fig. 2B in the online Data Supplement), and in
patients with additional symptoms suggestive of pneu-
monia (n  545; see Table 12 and Fig. 3 in the online
Data Supplement).
Performance of recommended cutoff concentrations. The
performance of currently recommended cutoff concen-
trations for the rule out of pneumonia is summarized in
Table 2. As an example, a procalcitonin concentration of
0.1 ng/mL or less provided a sensitivity of 71%.
RANDOMIZED MANAGEMENT STUDY
The management study was stopped early owing to the
unexpectedly low AUC of procalcitonin in the diagnostic
study. A total of 45 patients with AHF diagnosed in the
ED who in addition had suspected pneumonia were eli-
gible for randomization to intervention (procalcitonin
guidance, n  25) or control group (n  20) (see Fig. 4
in the online Data Supplement). Baseline characteristics
of the intervention and control group were similar (see
Table 13 in the online Data Supplement). There was
no significant difference in duration of antibiotic ther-
apy and length of hospital stay between the
procalcitonin-guided and standard group (Table 3).
When comparing baseline characteristics of patients
having antibiotic treatment stopped or continued in
the procalcitonin-guided therapy group, one signifi-
cant difference was found: left ventricular ejection
fraction was significantly lower in patients having con-
tinued antibiotic therapy on day 5 (see Table 14 in the
online Data Supplement).
Of 45 randomized patients, 30 (66.7%) underwent
CT scan of the chest whereby pneumonia was radio-
graphically confirmed in 19 patients (63.3%). At ran-
domization (day 0), the diagnostic accuracy of pro-
calcitonin and CRP for radiographically confirmed
pneumonia as quantified by the AUC was 0.76 (95% CI,
0.57–0.90) and 0.89 (95% CI, 0.72–0.92; P  0.28 for
comparison), respectively (see Fig. 5 in the online Data
Supplement).
Fig. 1. Diagnostic accuracy of procalcitonin, interleukin 6,
and CRP for the diagnosis of pneumonia (A) and pneumonia
with proven specific pathogen (B) assessed by the AUC in the
diagnostic study.
For (A), overall study population, n = 690; 178 patients thereof
with adjudicated final diagnosis of pneumonia. For (B), third sub-
group analysis, n=548; 36patients thereofwith pneumonia and
proven specific pathogen.
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Discussion
These prospective studies were performed to contribute
to advancing the knowledge regarding the clinical utility
of inflammatory biomarkers in the diagnosis and man-
agement of pneumonia. To the best of our knowledge,
the diagnostic study is the first direct comparison of pro-
calcitonin, CRP, and interleukin 6 against a reference
standard based on central adjudication by 2 independent
experts. We report 4 major findings.
First, in our diagnostic study in patients presenting
with acute dyspnea to the ED, when evaluated against
a final adjudicated diagnosis by 2 independent experts
based on current guidelines, the diagnostic accuracy of
procalcitonin for pneumonia was only moderate (AUC
0.75). As procalcitonin concentrations were available to
both clinicians and adjudicators in two-thirds of the pa-
tients, this point estimate likely may slightly overestimate
the true diagnostic accuracy of procalcitonin. This find-
ing is in full agreement with an AUC of 0.72 observed in
a similar diagnostic study using central adjudication with
complete blinding to procalcitonin (8 ). Second and
likely of most importance, CRP and particularly interleu-
kin 6, which was blinded in all patients, provided
significantly higher diagnostic accuracy when directly
compared to procalcitonin for the early diagnosis of
pneumonia. This finding is supported by observations
made in a large diagnostic study performed in primary
care with 2820 patients presenting with acute cough, of
whom 140 (5%) had pneumonia. CRP, but not procal-
citonin, increased the diagnostic accuracy for pneumonia
when added to the clinical information (29 ). Similarly, 2
Fig. 2. AUCs within the overall study population and each subgroup for the assessed biomarkers in the diagnostic study.
The interaction P values were calculated when comparing the AUC achieved in the overall study population to the AUC in each
subgroup.
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small single-center studies observed even slightly higher
diagnostic accuracy for CRP vs procalcitonin for the dif-
ferentiation of CAP vs exacerbation of asthma or chronic
obstructive pulmonary disease (30, 31 ).
In contrast, a single-center study enrolling 101 pa-
tients admitted to a medical intensive care unit found a
higher diagnostic accuracy for Procalcitonin than for
CRP and interleukin 6 for sepsis. This discrepancy may
at least in part be explained by the higher prevalence of
sepsis with established bacterial origin in that study than
in our diagnostic study (32 ).
Given the fact that the cost of measuring CRP in
most countries is 5% of that of procalcitonin, these
data suggest that the current American Infectious Dis-
eases Society of America/American Thoracic Society
guidelines favoring procalcitonin may need to be revised
and CRP or interleukin 6 should be considered the in-
flammatory biomarker of choice, complementing clinical
and radiographic assessment in the early diagnosis of
pneumonia (7 ). As CRP available and interleukin 6 un-
available to the adjudicating physician provided a similar
AUC in the diagnostic study, it is likely that the true
diagnostic accuracy of interleukin 6, which is secreted
earlier than CRP in response to bacterial infection (33 ),
is even higher than that of CRP. Future studies ideally
with blinded measurements of both biomarkers are war-
ranted to either confirm or reject this hypothesis. Third,
in the randomized management study of AHF patients
who in addition had suspected pneumonia, procalcitonin
guidance of the duration of antibiotic therapy resulted in
comparable duration of antibiotic therapy and length of
hospital stay. This finding is supported by a recent much
larger randomized study also showing no benefit of pro-
calcitonin guidance when compared against a contempo-
rary standard of care (12 ). In contrast, a subgroup anal-
ysis of patients with a history of chronic heart failure
enrolled in a randomized procalcitonin-guided antibiotic
stewardship trial found evidence of clinical benefit
in patients with low procalcitonin concentration (11 ).
Fourth, in the diagnostic part of the randomized man-
agement study with a CT scan as the reference standard,
again the diagnostic accuracy of procalcitonin was only
moderate (AUC, 0.76).
Overall, these findings corroborate and extend pre-
vious studies on procalcitonin (8, 18, 29–31, 33 ) and
help to put the seemingly contradictory conclusions into
perspective. A single low procalcitonin concentration in
patients presenting with suspected pneumonia to the ED
should not be used in isolation to withhold potentially
life-saving antibiotic therapy. Unfortunately, this has
become clinical practice in some institutions, although
scientifically incorrect. First, the findings of this study
clearly indicate that the diagnostic accuracy of procalci-
tonin is insufficient for this clinical consequence. Second,
previous open-label randomized controlled trials evaluat-
ing procalcitonin guidance in combination with the stan-
dard of care (always including CRP) did not withhold
antibiotic therapy based on a single measurement in iso-
lation but initiated antibiotic therapy in all patients and
stopped it after about 12 h in patients with persistently
low procalcitonin concentration and clinical stability (9–
11). Given the well-documented time delay in the rise in
Fig. 3. Diagnostic accuracy of interleukin 6, procalcitonin,
and CRP for the diagnosis of pneumonia assessed by the AUC
in case of procalcitonin available (A) and unavailable (B) for
the adjudicating physician in the diagnostic study.
For (A), first subgroupanalysis, n=452; 155patients thereofwith
adjudicated final diagnosis of pneumonia. For (B), second sub-
group analysis, n = 238; 23 patients thereof with adjudicated
final diagnosis of pneumonia.
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systemic concentrations of procalcitonin and CRP, this is
an essential difference, particularly in patients presenting
early after symptom onset (6, 17 ). In full agreement with
this concept, the results of this study document that es-
tablished low cutoffs for both procalcitonin and CRP do
not have sufficiently high negative predictive value to
reliably exclude CAP in general and pneumonia with
proven specific bacterial pathogen in particular.
For the second possible clinical consequence, short-
ening the duration of antibiotic therapy, it is important
to highlight that some, but not all, open-label random-
ized controlled trials evaluating procalcitonin guidance
in combination with the standard of care (always includ-
ing CRP) vs the local standard of care were able to show
a reduction in days on antibiotics (9–11, 34, 35 ). In
general, procalcitonin guidance was able to reduce the
number of days when the standard of care tended to
include rather long durations of treatment with poor
stewardship, but not when compared against a contem-
porary standard of care with strict stewardship.
Several limitations merit consideration when in-
terpreting our findings: first, no specific sample size
calculation was performed for this secondary analysis
of BASEL V. Although this is one of the largest diag-
nostic studies with central adjudication by 2 indepen-
dent experts performed until now, it might have been
underpowered for some comparisons. Second, al-
though we used one of the most stringent methods to
adjudicate for the presence or absence of pneumonia
including central adjudication, we may still have mis-
classified a small number of patients. However, this
misclassification would have resulted in an underesti-
mation of the true AUCs of all biomarkers examined
and could not explain the significantly higher AUC
observed for blinded interleukin 6 as compared to pro-
calcitonin mostly available to the adjudicating physi-
cian. Third, we cannot generalize our findings to pa-
tients with terminal kidney failure requiring dialysis
because these patients were excluded. Fourth, the ran-
domized management study was stopped prematurely
and therefore has limited statistical power.
In conclusion, in patients presenting with dyspnea,
diagnostic accuracy of procalcitonin for pneumonia is
only moderate and lower than that of interleukin 6 or
Table 2. Performance of currently recommended cutoff concentrations for the ruleout of pneumonia in the diagnostic study.
Biomarker Plasma concentration Sensitivity Negative predictive value
Effectivenessa (Percentage
fulfilling criteria, n)
Procalcitonin <0.1 ng/mL 0.71 (0.64–0.78) 0.87 (0.83–0.90) 55.0% (380)
Interleukin 6 <15 ng/L 0.83 (0.77–0.88) 0.91 (0.88–0.94) 49.6% (342)
CRP <10 mg/L 0.93 (0.88–0.96) 0.95 (0.91–0.97) 34.2% (236)
a The effectiveness shows the number of patients triaged toward ruleout (given the plasma concentration was below the mentioned cutoff) when presenting to the ED irrespective of
final diagnosis of pneumonia.




(n = 45) Intervention (n = 25) Control (n = 20) P valueb
Duration of antibiotic treatment, days 10.5 (6.8–13.0) 10.5 (6.0–12.2) 10.5 (8.8–13.2) 0.387
Duration of hospital stay, days 11.5 (6.0–22.5) 10.0 (6.0–18.2) 14.0 (6.8–24.2) 0.388
Inhospital mortality, n (%) 9 (20.5) 5 (20.8) 4 (20.0) 1.000
Endpoints
Patients randomized to
intervention (n = 25)
Antibiotic therapy
sustained (n = 15)
Antibiotic therapy
stopped (n = 10) P valuec
Duration of antibiotic treatment, days 10.5 (6.0–12.2) 12.0 (11.0–14.5) 6.0 (6.0–6.0) <0.001
Duration of hospital stay, days 10.0 (6.0–18.2) 16.0 (8.5–27.0) 6.0 (5.0–6.0) 0.004
Inhospital mortality, n (%) 5 (20.8) 4 (26.7) 1 (11.1) 0.697
a Continuous variables are presented as medians with interquartile ranges and categorical variables as numbers and percentages. For comparisons, Mann–Whitney U or chi-square
tests were used as appropriate.
b
P value for comparison between intervention and control group.
c
P value for comparison between antibiotic therapy sustained and stopped group.
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CRP. Overall, the clinical utility of procalcitonin was
lower than expected.
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